Lck Tyrosine Kinase Inhibitors (Merck & Co)

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug NameLck Tyrosine Kinase Inhibitors (Merck & Co)

Drug Alias NameN/A

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionTyrosine-protein kinase LCK inhibitors

TargetsTyrosine-protein kinase LCK

Therapy Area/IndicationsAutoimmune Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesMerck & Co Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesMerck & Co Inc

Active IndicationsN/A

Inactive IndicationsAutoimmune Diseases

ATC CodeN/A